We have been writing about (OTCQB:OXYS) and (OTCPK:RGBP) for sometime now, they have both have run up, come down, and are holding. Both have huge upsides and bright futures. No, neither is "Listed" on a Major Exchange, but both aspire.
http://www.barchart.com/quotes/stocks/OXYS
http://www.barchart.com/quotes/stocks/RGBP
Now would be the time, at opportune prices to take a serious look. In our opinion, and other 3rd Parties both in the future, will trade at much higher prices. Keep in mind when Warren Buffet is boasting of a company/stock he bought...more than likely he's selling to those getting in late/after him.
Timing is everything !! Both and are LONG Plays we believe, with short term Gain potential.
** It was mentioned during the recent "Investors" conference call that the company may very well, in the "Near" future be announcing, and rolling out a "New" product for the Military !!
At present the OxySure Model 615 is the ONLY Oxygen Device Allowed in the "Live Battle" Arena
http://www.oxysure.com/
CEO Ross Says Share Price is Ridiculously Low-He Begins Buying !!
Conversing with CEO Julian Ross this morning (5/27/15) he informed he has started buying . "He supports this great company that is growing exponentially (216% in 3 years)"
CEO Julian Ross stated "In my opinion, the stock is way underpriced, and undervalued. I see this as an excellent opportunity to build on my position and continue to do so for the near and mid term."
* Robust 75 % growth Q1 2015
* ALL Long Term Debt Retired
* ALL Capital Leases Retired
Estimated Revenue for 2015 if the Organic Sales Plan is fulfilled is $10 Million (up from $2.5 Million)
By Year end it is anticipated a total of 25-30 Territorial Sales managers will be in place. Each has a quota of $500,000 per year. That, if the quotas are met equates to 15 Million in New Revenue !! (Not all will be in place and fully producing by 2015 year end)
http://www.regenbiopharma.com/index.html
Regen BioPharma Files Patent Application on mRNA Dendritic Cell Cancer Immunotherapeutic
https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/4040176-regen-biopharma-files-patent-application-on-mrna-dendritic-cell-cancer-immunotherapeutic
Trades on the Pink Sheets and Bulletin Board, they are fully reporting.
Has 3 other "New Drugs" that await FDA Clearance. We believe approval of any of the 3 makes them a "Prime Candidate" to be bought out. (Chief Medical Director Thomas Ichim PhD was CEO of Medi Stem-Intrexeron bought them for $26 Million)
One of their "New Drug Protocols" they believe is in the "Final Phase" the "Last Step" to gaining FDA approval.
Now is the time to do your due diligence, and begin building for the possibility of the future. Will you be buying when others are selling down the road ?